RealFeedApp $1.2 billion milestone deal for protein design
Zealand Pharma and Generate Biomedicines signed a strategic collaboration to design multispecific protein therapeutics using AI for metabolic diseases. The initial plan includes two programs targeting obesity, with an option to add a third target.
- Field
- drugs and trials
- What they did
- Zealand Pharma signed a nearly $1.2 billion deal with Generate Biomedicines to design multispecific protein therapeutics.
- Why it matters
- This collaboration aims to develop drugs that can target multiple sites simultaneously to treat obesity and other metabolic diseases.
#protein therapy#obesity#ai drug discovery#zealand pharma#generate biomedicines
